DNAprint Genomics (DNAG)

[Bill H]

(PR NEWSWIRE) DNAPrint Technology Featured in 'Nature' Journal Review and Upcom
ng Textbook
DNAPrint Technology Featured in 'Nature' Journal Review and Upcoming Textbook

SARASOTA, Fla., July 22 /PRNewswire-FirstCall/ -- DNAPrint genomics
(OTC Bulletin Board: "DNAP") (the "Company") announces today that its
ANCESTRYbyDNA(TM) 2.5 product will be featured in a review article to be
published next month in the journal "Nature Reviews." The article will focus
on the growing interest in personal anthropology and will highlight the
uniqueness of DNAPrint's role in this growing market. The article represents
the first discussion of the Company's proprietary BioGeographical Ancestry
(BGA) admixture test in the peer-reviewed literature.
In addition, at the invitation of Academic Press Publishers, DNAPrint's
Chief Scientific Officer has agreed to co-author a textbook on the history,
molecular genetics, mathematics and practice of molecular photo fitting
entitled "Molecular Photo Fitting: Predicting Ancestry and Phenotype Using
DNA." Dr. Mark Shriver, a co-author of the Nature Review article, was invited
by DNAPrint to join the project as a co-author. The Company expects the work,
targeted for publication March 1, 2006, to serve as the interface between the
Company's unique pharmacogenomics/forensics platform and the scientific
community.

About DNAPrint genomics, Inc.
DNAPrint genomics Inc. uses proprietary human genome research methods to
develop genomic-based services and products. The Company introduced
ANCESTRYbyDNA in the consumer market and DNAWitness in the forensic market in
2003. DNAPrint is developing products in the pharmacogenomic market and has a
disease gene discovery program. The Company is traded on the Nasdaq OTC
Bulletin Board under the ticker symbol: DNAP. For more information about the
company, please visit http://www.dnaprint.com.

All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities
Exchange Act, as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.

Media and Press Contacts:
Richard Gabriel
DNAPrint genomics, Inc. CEO/President
[phone]

SOURCE DNAPrint genomics, Inc.
-0- 07/22/2004
/CONTACT: Richard Gabriel, CEO and President, DNAPrint genomics, Inc.,
[phone]/
/Web site: http://www.dnaprint.com/
(DNAP)

CO: DNAPrint genomics, Inc.
ST: Florida
IN: MTC OTC PUB
SU:
*** end of story ***